INHIBRX, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 34.01 USD | -0.85% |
|
-1.08% | -10.50% |
| 28/02 | Inhibrx Shares Fall After Q4 Net Loss Widens | MT |
| 28/02 | Earnings Flash (INBX) INHIBRX Reports Q4 Revenue $1.6M | MT |
Chart calendar Inhibrx, Inc.
436be9a3f7ed650d628436.VV4gsZNKZb7P_eS96Q92M5uvGz0odiP7IiEcrKIRKuc.Jm9j6_YEIPeshLbL3TgkS8GWWHxGOhOzE2cs2ZdWYr0jDhD4oX487JyVsQ~bee761da05e252f5646722c17ce7ffb4
Upcoming events on Inhibrx, Inc.
Past events on Inhibrx, Inc.
| 28/02/2024 07:45 pm | Q4 2023 Earnings Release |
| 10/11/2023 02:30 am | Q3 2023 Earnings Release |
| 04/11/2023 09:30 pm | Society for Immunotherapy of Cancer Meeting - Abstract: 742 |
| 04/11/2023 09:30 pm | Society for Immunotherapy of Cancer Meeting - Abstract: 748 |
| 02/11/2023 10:00 pm | Connective Tissue Oncology Society Meeting |
| 08/08/2023 01:30 am | Q2 2023 Earnings Release |
| 25/05/2023 10:30 pm | Annual General Meeting |
| 09/05/2023 01:35 am | Q1 2023 Earnings Release |
| 07/03/2023 02:35 am | Q4 2022 Earnings Release |
| 30/11/2022 10:15 pm | Evercore ISI HealthCONx Conference |
| 20/11/2022 03:06 am | Connective Tissue Oncology Society Meeting - Abstract: 2206531 |
| 18/11/2022 03:30 am | Connective Tissue Oncology Society Meeting - Abstract: 2206600 |
| 18/11/2022 03:30 am | Connective Tissue Oncology Society Meeting - Abstract: 2206541 |
| 16/11/2022 | Connective Tissue Oncology Society Conference |
| 11/11/2022 07:30 pm | Society for Immunotherapy of Cancer Meeting - Abstract: 1077 |
| 10/11/2022 07:30 pm | Society for Immunotherapy of Cancer Meeting - Abstract: 1077 |
| 08/11/2022 02:35 am | Q3 2022 Earnings Release |
| 01/11/2022 06:00 pm | American Conference on Pharmacometrics Meeting - Abstract ID: PMX436 |
| 04/10/2022 06:00 pm | INBRX-101 Update Call |
| 08/08/2022 | Interim 2022 Earnings Release (Projected) |
Annual results
| Fiscal Period | December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 12,9 11,1 16.11% | 7,23 6,10 18.54% | 2,19 2,60 -15.69% | 1,80 0,25 620% | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | -66,4 -70,7 6.03% | -75,4 -78,0 3.37% | -128 -125 -2.31% | 0,00 0,00 - | 0,00 |
|
EBIT Million USD | Released Forecast Spread | -67,4 -71,8 6% | -76,6 -78,2 2.06% | -129 -126 -2.15% | -219 -178 -23.47% | -199 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -75,6 -81,5 7.14% | -81,8 -82,9 1.38% | -145 -135 -7.34% | -240 -197 -21.5% | -199 |
|
Net income Million USD | Released Forecast Spread | -76,1 -81,7 6.82% | -81,8 -82,9 1.38% | -145 -139 -4.59% | -241 -197 -22.33% | -199 |
|
EPS USD | Released Forecast Spread | -3,01 -2,95 -2.21% | -2,15 -2,15 0.19% | -3,62 -3,36 -7.67% | -5,12 -4,39 -16.54% | -3,94 |
| Announcement Date | 12/03/21 | 28/02/22 | 06/03/23 | 28/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 2,86 1,71 67.02% | 0,93 1,10 -15.8% | 0,71 1,07 -33.55% | 0,28 0,57 -50.94% | 0,27 0,79 -65.46% | 0,02 0,10 -83% | 0,03 0,00 - | 0,12 0,00 - | 1,63 0,05 3168% | 0,00 | 0,00 | 0,00 | 0,00 |
|
EBIT Million USD | Released Forecast Spread | -19,4 -21,0 7.6% | -29,0 -23,3 -24.38% | -34,6 -29,5 -17.42% | -30,0 -36,1 16.83% | -35,5 -32,8 -8.29% | -43,8 -36,0 -21.52% | -41,3 -43,2 4.21% | -45,8 -43,2 -6.05% | -88,3 -46,6 -89.33% | -47,9 | -48,1 | -50,5 | -52,7 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -21,2 -21,3 0.43% | -31,3 -24,4 -28.17% | -37,7 -33,0 -14.43% | -35,3 -39,6 10.7% | -40,9 -33,0 -24.06% | -48,9 -36,9 -32.49% | -47,0 -45,0 -4.52% | -51,8 -46,0 -12.67% | -92,0 -49,5 -85.69% | -47,9 | -48,1 | -50,5 | -52,7 |
|
Net income Million USD | Released Forecast Spread | -21,2 -21,3 0.43% | -31,3 -24,4 -28.17% | -37,7 -33,0 -14.44% | -35,3 -39,6 10.7% | -40,9 -33,0 -24.05% | -48,9 -36,9 -32.49% | -47,1 -45,0 -4.53% | -51,8 -46,0 -12.67% | -93,6 -49,5 -88.98% | -47,9 | -48,1 | -50,5 | -52,7 |
|
EPS USD | Released Forecast Spread | -0,55 -0,57 4.07% | -0,80 -0,60 -33.33% | -0,97 -0,78 -24.76% | -0,90 -0,94 4.26% | -0,95 -0,79 -20.63% | -1,12 -0,84 -32.81% | -1,08 -1,03 -4.52% | -1,10 -1,01 -8.91% | -1,73 -1,04 -66.88% | -1,01 | -1,02 | -0,96 | -0,92 |
| Announcement Date | 28/02/22 | 09/05/22 | 08/08/22 | 07/11/22 | 06/03/23 | 08/05/23 | 07/08/23 | 09/11/23 | 28/02/24 | - | - | - | - |
More events
Past sector events for Inhibrx, Inc.
| 03/05/2024 01:31 am | ASCENDIS PHARMA A/S: Q1 2024 Earnings Release |
| 02/05/2024 08:30 pm | GENMAB A/S: Q1 2024 Earnings Release |
| 02/05/2024 04:30 pm | AGIOS PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
| 02/05/2024 04:00 pm | SPRINGWORKS THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 02/05/2024 04:00 pm | REGENERON PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
| 02/05/2024 03:30 pm | AURINIA PHARMACEUTICALS INC.: Q1 2024 Earnings Release |
| 02/05/2024 | ZENTALIS PHARMACEUTICALS, INC.: Q1 2024 Earnings Release (Projected) |
| 02/05/2024 | DENALI THERAPEUTICS INC.: Q1 2024 Earnings Release (Projected) |
| 02/05/2024 | GERON CORPORATION: Q1 2024 Earnings Release |
| 02/05/2024 | KURA ONCOLOGY, INC.: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- INBX Stock
- Calendar Inhibrx, Inc.
